GlycoMimetics scientists have rationally designed a highly-potent antagonist of E-selectin, GMI-1687, that is 100% bioavailable following subcutaneous (SC) administration in animals.
Overexpression of E-selectin is a key driver of multicellular adhesion (sticky clusters of blood cells to form / interact with activated endothelial vasculature) and vaso-occlusive crisis (VOC; a reduction/occlusion in blood flow in the vessels induces pain, hypoxia and organ damage) in patients with sickle cell disease. Based on the recent clinical data demonstrating the importance of early targeted intervention targeting the selectins in patients with VOC, we believe that GMI-1687 is ideally suited for VOC as it can potentially be self-administration at the time of onset to disrupt the underlying inflammatory cascade and restore normal blood flow. We are currently conducting investigational new drug (IND)-enabling studies with GMI-1687 to support first-in-human dosing in 2022.
GMI-1687 has not been approved for use by any health authority anywhere in the world.
If you are interested in partnering for uproleselan, please email: firstname.lastname@example.org